The Chase Group is pleased to continue partnership with Marinus in building their leadership team with the recent placement of the Vice President of Clinical Development and Pharmacovigilance. The successful candidate will be responsible for the medical leadership of the postpartum depression (PPD) programs and drug safety.
This executive’s experience in clinical development within the neuropsychiatric and CNS therapies will be instrumental as Marinus completes its Phase 2 trials in PPD and continues to develop its later-stage development strategy in depression.
Marinus Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the development of ganaxolone, which offers a new mechanism of action, demonstrated efficacy and safety, and convenient dosing to improve the lives of patients suffering from epilepsy and neuropsychiatric disorders.
The Chase Group Places VP of Clinical Development and Pharmacovigilance at Marinus Pharmaceuticals
The Chase Group is pleased to continue partnership with Marinus in building their leadership team with the recent placement of the Vice President of Clinical Development and Pharmacovigilance. The successful candidate will be responsible for the medical leadership of the postpartum depression (PPD) programs and drug safety.
This executive’s experience in clinical development within the neuropsychiatric and CNS therapies will be instrumental as Marinus completes its Phase 2 trials in PPD and continues to develop its later-stage development strategy in depression.
Marinus Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the development of ganaxolone, which offers a new mechanism of action, demonstrated efficacy and safety, and convenient dosing to improve the lives of patients suffering from epilepsy and neuropsychiatric disorders.- Categories: Life Sciences, Pharmaceutical
The Chase Group Successfully Secures Vice President, Head of Medical Development for Checkmate Pharmaceuticals
Building on a 14+ year relationship with Chase, the Chief Medical Officer of Checkmate Pharmaceuticals retained The Chase Group to identify a critical hire for…
Search Executed by The Chase Group, Inc. Results in Successful Appointment of Dr. Christophe Hotermans as SVP, Global Medical Affairs for Akcea Therapeutics
The Chase Group was once again retained by Akcea Therapeutics to complete an extensive executive search on an accelerated timeline for a Senior Vice President,…-
Appointment of William Andrews, M.D. as Chief Medical Officer at Akcea Therapeutics Successfully Completed by The Chase Group
The Chase Group, known for relationship building with proven success in life sciences executive search, was retained by Akcea Therapeutics, to identify and secure a… 
Biologics Consulting Leadership Team Grows Through Partnership with The Chase Group
Through focused collaboration with The Chase Group, Biologics Consulting has entered a season of growth by successfully placing, in a newly created position, a Director,…
The Chase Group Secures New Leader for Informatics & Computational Biology at the Allen Institute for Immunology
Following an extensive search of industry and academic professionals by The Chase Group, the Allen Institute for Immunology welcomes a new Director, Informatics & Computational…-
The Chase Group Successfully Completes the Appointment of Carla Poulson as Senior Vice President/Chief Human Resources Officer at Akcea Therapeutics
After a comprehensive executive search that was filled in less than two months, The Chase Group is pleased to announce the placement of Carla Poulson…